Suven Life Sciences Limited (SUVEN) fundamentals
Suven Life Sciences Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as SUVEN (ISIN INE495B01038). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Suven Life Sciences Limited does
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Valuation and market data
| Last close | ₹355.55 |
|---|---|
| Market capitalisation | ₹8,100 crore |
| Enterprise value | ₹8,104 crore |
| P/E (TTM) | 0.00 |
| Price to book | 13.70 |
| Price to sales (TTM) | 284.41 |
| Book value per share | ₹25.96 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Thu Oct 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹21 crore | ₹-276 crore | ₹-276 crore | -12.13 |
| Mar 2025 | ₹18 crore | ₹-161 crore | ₹-161 crore | -7.37 |
| Mar 2024 | ₹33 crore | ₹-106 crore | ₹-105 crore | -4.82 |
| Mar 2023 | ₹22 crore | ₹-118 crore | ₹-118 crore | -5.42 |
| Mar 2022 | ₹13 crore | ₹-122 crore | ₹-122 crore | -9.05 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Aug 2026:
| Promoters | 65.5% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.7% |
| Retail and others | 31.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.